论文部分内容阅读
奈西利肽(重组B型脑钠肽)因降低肺毛细血管楔压,改善呼吸困难而被批准用于急性心力衰竭。但是批准之后,奈西利肽对急性心衰患者肾功能的影响引起了很大争议。一项纳入5项随机试验的荟萃分析显示静脉注射奈西利肽使肾功能恶化增加50%,而ASCEND-HF(奈西利肽治疗失代偿心力衰竭临床疗效研究)表明奈西利肽不改善(或恶化)临床转归,也不进一步恶化肾功能。针对上述争议性结论,来自荷兰格罗宁根大学的Voors博士等对ASCEND-HF研究进行了回顾性分析,旨在研究奈西利肽对急性失代偿心衰患者住院期间肾功能影响以及与临床预后的相关性。研究表明奈西利肽不影响
Nesylate (recombinant brain natriuretic peptide) is approved for acute heart failure due to decreased pulmonary capillary wedge pressure and improved breathing. However, the approval of NICE after acute renal failure in patients with acute renal failure caused great controversy. A meta-analysis of five randomized trials showed that intravenous nesiritide increased renal function by 50%, whereas ASCEND-HF (a clinical study of necyliotide for decompensated heart failure) showed no improvement of nesiritide (or Worsening) clinical outcome, nor further deterioration of renal function. In response to the controversial findings, Dr. Voors et al from the University of Groningen, The Netherlands, conducted a retrospective analysis of the ASCEND-HF study in order to study the effects of nesiritide on renal function during hospitalization in patients with acute decompensated heart failure and their association with clinical outcomes Correlation. Studies have shown that nissyritin does not affect